HIV Vaccines (X8)

joint with the meeting on HIV Persistence: Pathogenesis and Eradication (X7)

Scientific Organizers: David C. Montefiori and Mario Roederer


March 20—24, 2016

Resort at Squaw Creek, Olympic Valley, California, USA


Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.


BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

** Meeting has ended **

Discounted Abstract Deadline: November 19, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time

Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is December 17, 2015)

Global Health Travel Award Deadline: October 20, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: November 19, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: December 17, 2015

*All deadlines end at 11:59 PM US Mountain Standard Time


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:

  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is November 19, 2015)

Discounted Registration Deadline: January 21, 2016

*All deadlines end at 11:59 PM US Mountain Standard Time


Registration Fee: 795.00 USD* (includes 150.00 USD discount)
Student Registration Fee: 570.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 945.00 USD*
Student Registration Fee: 720.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that some meeting participants have received calls and emails from a number of different housing services, including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a lodging reservation with them.

We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.

Meeting Summary



The development of a safe and effective HIV vaccine remains a major global health priority and a complex problem to solve. Current efforts emphasize an ability to elicit systemic and mucosal antibody responses capable of preventing the acquisition of infection. Evidence from multiple passive transfer experiments in non-human primates, as well as from studies of immunologic correlates of modest efficacy in the RV144 Thai trial, support the notion that both neutralizing and non-neutralizing antibodies have potential to prevent infection. Major advances have been made in understanding the epitopes, structures and evolutionary pathways of broadly neutralizing antibodies, leading to new avenues to pursue for vaccine design. The extraordinary breadth and potency of some recently discovered neutralizing antibodies has generated additional interest in potential therapeutic applications, including cure strategies. There has also been a steady increase in knowledge of other types of antiviral antibodies and their effector functions that may be important for vaccines. This meeting aims to cover a range of topics including: 1) Initial virus transmission events for vaccine intervention, 2) Non-neutralizing antibody correlates of sterilizing immunity; 3) Epitopes, structures and ontogeny of broadly neutralizing antibodies; 4) Novel vaccine concepts for broadly neutralizing antibody induction; and 5) Immunotherapy. Emphasis will be placed on recent unpublished findings in key areas that hold the greatest promise for rapid progress toward an effective vaccine.